EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors

Christopher Willy Schwarz iD, Charlotte Näslund-Koch iD, Claus Zachariae iD, Jakob Benedict Seidelin iD, Susanne Dam Nielsen iD, Sisse Rye Ostrowski iD, Karen Marie Thyssen Astvad iD, Inger Brock, Lars Iversen iD, Mads Kirchheiner Rasmussen iD, Nikolai Loft iD, Lone Skov iD

Acta Dermato-Venereologica · 2025

DOI: 10.2340/actadv.v105.43685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Christopher Willy Schwarz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, Un…. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Adalimumab, Candidiasis, Oral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-17 inhibitors are effective in psoriasis; however, they are associated with an increased risk of infections, particularly oral candidiasis, and new-onset/flares of inflammatory bowel disease. This study aimed to identify predictive markers for these adverse events and to describe the functional immune response in patients treated with interleukin-17 inhibitors using a whole-blood stimulation system (TruCulture®). Patients with psoriasis initiating an interleukin-17 inhibitor (n = 36) or adalimumab (n = 24) were enrolled. Patients attended visits at baseline, week 12, and week 52, during which skin and mucosal swabs, and faecal and blood samples were collected. Baseline oral Candida albicans colonization with no clinical symptoms was associated with an increased risk of oral candidiasis during the first year of interleukin-17 inhibitor therapy, with no cases of oral candidiasis observed in the adalimumab group. Gut inflammation, measured by faecal calprotectin, remained stable in both the adalimumab and interleukin-17 inhibitor group. Colonization with Staphylococcus aureus did not change during treatment. It was found that interleukin-17 inhibitors induced an anti-inflammatory state and potentially more active toll-like receptor 3-mediated antiviral responses compared with adalimumab. In conclusion, screening for oral Candida albicans colonization prior to initiation of interleukin-17 inhibitor therapy may be a useful strategy for risk stratification and early intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-17AdalimumabCandidiasis, OralAntibodies, Monoclonal, HumanizedOpportunistic InfectionsHumansMaleFemaleMiddle AgedAdultCandida albicansFecesTreatment OutcomeRisk FactorsTime FactorsAgedLeukocyte L1 Antigen ComplexInflammatory Bowel Diseases

Substanzen

Interleukin-17AdalimumabAntibodies, Monoclonal, HumanizedLeukocyte L1 Antigen ComplexIL17A protein, humansecukinumab

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. christopher.willy.schwarz…
  • 1Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
  • Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Digestive Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Immunology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Christopher Willy Schwarz, Charlotte Näslund-Koch, Claus Zachariae, Jakob Benedict Seidelin, Susanne Dam Nielsen, Sisse Rye Ostrowski, Karen Marie Thyssen Astvad, Lars Iversen, Mads Kirchheiner Rasmussen, Nikolai Loft, Lone Skov

Zitieren

APA

Schwarz, C. W., Näslund-Koch, C., Zachariae, C., Seidelin, J. B., Nielsen, S. D., Ostrowski, S. R., Astvad, K. M. T., Brock, I., Iversen, L., Rasmussen, M. K., Loft, N., & Skov, L. (2025). Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.43685

Vancouver

Schwarz CW, Näslund-Koch C, Zachariae C, Seidelin JB, Nielsen SD, Ostrowski SR, et al. Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.43685

BibTeX
@article{Schwarz2025,
  author = {Schwarz, Christopher Willy and Näslund-Koch, Charlotte and Zachariae, Claus and Seidelin, Jakob Benedict and Nielsen, Susanne Dam and Ostrowski, Sisse Rye and Astvad, Karen Marie Thyssen and Brock, Inger and Iversen, Lars and Rasmussen, Mads Kirchheiner and Loft, Nikolai and Skov, Lone},
  title = {Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors},
  journal = {Acta Dermato-Venereologica},
  year = {2025},
  doi = {10.2340/actadv.v105.43685}
}
Kostenlos starten →